OSE Immunotherapeutics — ASCO 2025 update showcases Tedopi potential
OSE Immunotherapeutics presented multiple updates at the 61st Annual American Society of Clinical Oncology Conference (ASCO 2025) related to...
265 Views
OSE Immunotherapeutics — Strategic collaboration in mRNA technologies
OSE Immunotherapeutics has announced a new strategic collaboration with Inside Therapeutics and MiNT Laboratory (University of Angers) to develop...
287 Views
OSE Immunotherapeutics — Lusvertikimab impresses in extension period data
OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of...
267 Views
OSE Immunotherapeutics — Primed for value appreciation
OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The...
247 Views
OSE Immunotherapeutics — KOL event highlights lusvertikimab’s potential
OSE Immunotherapeutics and Edison held a key opinion leader (KOL) event on 5 March 2025, providing up-to-date insights into OSE’s lead...
85 Views